P\" Project 1 Management I&. Institute. ASTRAZENECA Fighting a Global Pandemic CHALLENGE: From Lab to Jab at Light Speed As COVlD-19 spread throughout the world in the spring of 2020, AstraZeneca recognized the need for an effective COVlD-19 vaccine to defeat the virus. In April 2020 AstraZeneca joined forces with the University of Oxford to make a meaningful difference and save lives. This landmark partnership brought together world-class expertise in vaccinology with AstraZeneca's ability to deliver a global solution at scale. AstraZeneca's research partners at Oxford University had demonstrated an immune response in preclinical studies and some encouraging early clinical results that provided a basis for confidence that a vaccine could be rapidly developed. AstraZeneca's proven manufacturing capability and global supply chain would enable rapid progress from the research lab to the development of a highly effective vaccine, with a favorable safety profile that could be administered around the world. AstraZeneca and Oxford University pledged to provide the vaccine on a not-for-prot basis. This commitment to broad and equitable access ensured that the vaccine would be available at cost during the pandemic, and accessible to low-income countries after the pandemic subsides. To be successful, however, AstraZeneca would have to make every dollar count. AstraZeneca is a global bio- pharmaceutical company headquartered in Cambridge, England, with revenues of $26.6 billion (2020). Key Results As ofJuly 2021, AstraZeneca has released 1 billion doses for supply to 170 countries